AZTR Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.57%

Insider Buying (Last 12 Months): $115,471.80

Insider Selling (Last 12 Months): $0.00

Azitra Insider Trading History Chart

Azitra Share Price & Price History

^$0.44

▲ +0.0193 (4.54%)

As of 01/2/2025 06:34 PM ET

Days: 30 | 90 | 365

Is Starlink Set For The Largest IPO In History?

From Paradigm Press | Ad

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!

Click here now for the urgent details.

Azitra Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/29/2024	Norm Staskey	CFO	Buy	1,586	$6.30	$9,991.80	1,703
2/13/2024	Francisco D Salva	CEO	Buy	11,110	$9.00	$99,990.00	11,276
2/13/2024	Norm Staskey	CFO	Buy	110	$9.00	$990.00	116
2/13/2024	Travis Whitfill	COO	Buy	500	$9.00	$4,500.00	11,150
6/21/2023	Leslie W Kreis	Major Shareholder	Buy	20,000	$150.00	$3,000,000.00	58,255

⭕ [URGENT] Buy Alert just triggered

From Behind the Markets | Ad

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>

SEC Filings (Institutional Ownership Changes) for Azitra (NYSEAMERICAN:AZTR)

11.16% of Azitra stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Azitra Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company	Details
11/14/2023	Knollwood Investment Advisory LLC	41,537	$62K	0.0%	N/A	0.343%
11/13/2023	Warberg Asset Management LLC	35,000	$52K	0.0%	+20.7%	0.289%

Data available starting January 2016

Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.

Today's Range

Now: $0.44

$0.43

$0.45

50 Day Range

MA: N/A

52 Week Range

Now: $0.44

$0.38

$68.40

Volume

219,291 shs

Average Volume

806,801 shs

Market Capitalization

$3.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Azitra?: Azitra's top insider investors include:
Leslie W Kreis (Major Shareholder)
Francisco D Salva (CEO)
Travis Whitfill (COO)
Norm Staskey (CFO)
Learn More about top insider investors at Azitra.